Expedited revascularization through pharmacologic dissolution and/or mechanical thrombectomy is the principle goal of treatment of ischemic stroke . Pharmacologic therapy consists of intravenous thrombolysis with tissue plasminogen activator and is limited by a narrow time window within which to administer the medication, resulting in less than 10% utilization in stroke patients. Mechanical thrombectomy provides another option for flow recanalization. Four thrombectomy devices are cleared by the FDA to restore blood flow in ischemic stroke patients, namely, the Merci retriever, the Penumbra aspiration system, the Solitaire FR revascularization device, and the Trevo device. While several completed and ongoing clinical trials have shown enhancement in the design of thrombectomy devices and increase in recanalization rate [2–4], the recanalization rate and, more importantly, the clinical outcome achieved with current thrombectomy devices still remain to be optimized.
- Bioengineering Division
The Use of Stentrievers in Acute Ischemic Stroke: Performance Evaluation in a Patient-Specific Vascular Replica
- Views Icon Views
- Share Icon Share
- Search Site
Chueh, J, Kuhn, AL, Puri, AS, Wakhloo, AK, & Gounis, MJ. "The Use of Stentrievers in Acute Ischemic Stroke: Performance Evaluation in a Patient-Specific Vascular Replica." Proceedings of the ASME 2013 Summer Bioengineering Conference. Volume 1A: Abdominal Aortic Aneurysms; Active and Reactive Soft Matter; Atherosclerosis; BioFluid Mechanics; Education; Biotransport Phenomena; Bone, Joint and Spine Mechanics; Brain Injury; Cardiac Mechanics; Cardiovascular Devices, Fluids and Imaging; Cartilage and Disc Mechanics; Cell and Tissue Engineering; Cerebral Aneurysms; Computational Biofluid Dynamics; Device Design, Human Dynamics, and Rehabilitation; Drug Delivery and Disease Treatment; Engineered Cellular Environments. Sunriver, Oregon, USA. June 26–29, 2013. V01AT12A006. ASME. https://doi.org/10.1115/SBC2013-14634
Download citation file: